Dakota Wealth Management Makes New $396,000 Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Dakota Wealth Management bought a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 6,206 shares of the biopharmaceutical company's stock, valued at approximately $396,000.

Other hedge funds have also recently made changes to their positions in the company. Penserra Capital Management LLC bought a new stake in shares of Halozyme Therapeutics during the 1st quarter valued at $125,000. Bessemer Group Inc. grew its position in Halozyme Therapeutics by 62.9% during the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock worth $34,000 after acquiring an additional 207 shares during the last quarter. D. E. Shaw & Co. Inc. lifted its holdings in Halozyme Therapeutics by 171.2% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company's stock worth $39,750,000 after buying an additional 524,802 shares during the period. Fifth Third Bancorp raised its position in shares of Halozyme Therapeutics by 29.4% in the 1st quarter. Fifth Third Bancorp now owns 10,017 shares of the biopharmaceutical company's stock worth $639,000 after acquiring an additional 2,276 shares in the last quarter. Finally, GAMMA Investing LLC increased its position in Halozyme Therapeutics by 199.0% during the 1st quarter. GAMMA Investing LLC now owns 2,802 shares of the biopharmaceutical company's stock valued at $179,000 after buying an additional 1,865 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $56.43, for a total transaction of $1,128,600.00. Following the completion of the transaction, the chief executive officer owned 733,719 shares in the company, valued at $41,403,763.17. This trade represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Jeffrey William Henderson sold 4,497 shares of the firm's stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $60.37, for a total transaction of $271,483.89. Following the completion of the transaction, the director owned 28,611 shares of the company's stock, valued at $1,727,246.07. This trade represents a 13.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 64,497 shares of company stock valued at $3,533,884. 2.40% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Wells Fargo & Company boosted their target price on Halozyme Therapeutics from $60.00 to $65.00 and gave the company an "equal weight" rating in a research report on Wednesday, May 7th. HC Wainwright reiterated a "buy" rating and issued a $72.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, May 29th. Benchmark downgraded shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 7th. The Goldman Sachs Group began coverage on shares of Halozyme Therapeutics in a research report on Thursday, July 10th. They set a "neutral" rating and a $55.00 price objective for the company. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Halozyme Therapeutics from $58.00 to $60.00 and gave the company a "neutral" rating in a research note on Wednesday. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $62.70.

Halozyme Therapeutics Stock Down 0.3%

Shares of NASDAQ HALO opened at $57.81 on Friday. The company has a market capitalization of $7.12 billion, a price-to-earnings ratio of 15.38, a price-to-earnings-growth ratio of 0.39 and a beta of 1.15. The company has a debt-to-equity ratio of 3.13, a current ratio of 8.39 and a quick ratio of 7.30. The business has a 50-day moving average of $54.48 and a two-hundred day moving average of $57.15. Halozyme Therapeutics, Inc. has a 1 year low of $42.01 and a 1 year high of $70.51.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 EPS for the quarter, topping analysts' consensus estimates of $0.98 by $0.13. Halozyme Therapeutics had a return on equity of 136.91% and a net margin of 44.76%. The business had revenue of $264.86 million during the quarter, compared to the consensus estimate of $231.21 million. During the same period last year, the firm earned $0.79 earnings per share. The company's revenue for the quarter was up 35.2% compared to the same quarter last year. On average, analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.